Showing 1-10 of about 45 articles.
Endologix
Endologix to Participate in Three Upcoming Investor Conferences
IRVINE, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate in three upcoming investor conferences in May and June. The first conference is the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas. The Bank of America Merrill Lynch conference includes a formal presentation.
Endologix
Endologix Announces FDA Approval of First Percutaneous Indication for Endovascular Abdominal Aortic Aneurysm Repair
IRVINE, Calif., April 16, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement for a broadened indication for the Company's 21Fr profile and smaller EVAR systems to include totally percutaneous endovascular aneurysm repair (PEVAR) based upon the outcomes of the first prospective, multicenter, randomized clinical trial (The PEVAR Trial). The Endologix EVAR platforms include the Powerlink
Endologix
Endologix Board Member Roderick de Greef to Retire; Thomas F. Zenty, III to Stand for Election as Board Member
IRVINE, Calif., April 15, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Roderick de Greef will retire from the Board of Directors at the end of his current term, which ends on May 23, 2013, the date of the Company's annual shareholder meeting. Thomas F. Zenty, III will stand for election as a Class III director to fill the resulting vacant position at the upcoming annual shareholder meeting.
Endologix
Endologix to Report First Quarter 2013 Financial Results on April 30, 2013
IRVINE, Calif., April 8, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its first quarter 2013 financial results, which will take place on Tuesday, April 30, 2013 after the close of the market.
Endologix
Endologix to Present at the 25th Annual ROTH Conference
IRVINE, Calif., March 11, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer and Shelley Thunen, Chief Financial Officer, are scheduled to present at the 25th Annual ROTH Conference in Laguna Niguel, CA.
Endologix
Endologix to Report Fourth Quarter and Full Year 2012 Financial Results on February 27, 2013
IRVINE, Calif., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2012 financial results, which will take place on Wednesday, February 27, 2013 after the close of the market.
Endologix
Endologix Announces Presentation of Data From PEVAR Randomized Trial
IRVINE, Calif., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was recently presented at two medical meetings. The presentation on the closure device independent substudy was made by Zvonimir Krajcer, MD (Program Director - Peripheral Vascular Interventions, Department of Cardiology, St. Luke's Episcopal Hospital at the Texas Heart Institute, Houston, TX) at the 25
Endologix
Endologix Receives CE Mark for Nellix(R) EndoVascular Aneurysm Sealing System
IRVINE, Calif., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms ("AAA"). Nellix is the first available endovascular aneurysm sealing ("EVAS") system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular AAA procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.
Showing 1-10 of about 45 articles.